Chromium Picolinate For Insulin Resistance In Subjects With HIV Disease: A Pilot Study
| 効果 | なし |
| 試験方法 | コホート法 |
| 試験期間 | 1-6 ヶ月 |
| 被験者数 | 8 |
| 性別 | 男女 |
| 年齢 | 30-44, 45-64 |
| 体型 | 肥満 |
この研究の注釈：
In persons with HIV (where drug therapy is associated with increased risk for insulin resistance) given supplemental chromium at 1mg daily as picolinate, supplementation was associated with a 25% increase in glucose disposal rate as assessed by hyperinsulinaemic–euglycaemic insulin clamp.
In persons with HIV (where drug therapy is associated with increased risk for insulin resistance) given supplemental chromium at 1mg daily as picolinate, supplementation was associated with a 25% increase in glucose disposal rate as assessed by hyperinsulinaemic–euglycaemic insulin clamp.
There was no influence on viral titres or lymphocytes, and two persons experienced increases in liver enzymes (relationship to chromium uncertain).
